{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-007911","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2022-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.519493+00:00","generated_at":"2026-06-27T07:56:09.145248+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"OptimizeRx preliminary Q4 revenue ~$20.3M record; guides 2022 revenue $80-85M","bullets":["Preliminary Q4 2021 revenue ~$20.3M (record); full-year revenue rose 42% YoY.","GAAP net income $0.6M; record quarterly adjusted EBITDA $4.0M.","2022 guidance: revenue $80-85M (31-39% growth); gross margins 57-60%.","New KPIs: avg revenue per top-20 pharma manufacturer $2.5M; net revenue retention 127%; revenue per FTE $730K.","Top 20 pharma customer penetration increased to 95% from 85% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-007911","json":"https://secwatch.observer/filing/0001213900-22-007911.json","markdown":"https://secwatch.observer/filing/0001213900-22-007911.md","text":"https://secwatch.observer/filing/0001213900-22-007911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022007911/0001213900-22-007911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022007911/ea155745-8k_optimizerx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T07:56:09.145248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}